Viewing Study NCT06227156


Ignite Creation Date: 2025-12-24 @ 11:36 PM
Ignite Modification Date: 2026-01-05 @ 5:36 PM
Study NCT ID: NCT06227156
Status: RECRUITING
Last Update Posted: 2024-05-23
First Post: 2024-01-17
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer
Sponsor: RemeGen Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module